The primary objective of this open-label, Phase I, trial is to evaluate the toxicity profile
of intraperitoneal talimogene laherparepvec (TVEC) in patients with peritoneal surface
dissemination from gastrointestinal or recurrent, platinum-resistant ovarian tumors. The
secondary objectives are to evaluate the pharmacokinetic profile and viral shedding of TVEC
by measuring viral load in serum and urine as well as viral load in peritoneal washings.
This is a non-randomized, open-label Phase I trial in patients with Stage IV peritoneal
surface dissemination from gastrointestinal or recurrent, platinum-resistant ovarian tumors
enrolled at Duke Cancer Institute. All subjects will complete an extensive medical history,
baseline physical examination and clinical assessment to ensure subject eligibility
requirements within 4 weeks of starting study drug. All eligible patients must have a
peritoneal catheter placed at least 2 weeks prior to the initiation of therapy. All patients
will receive an initial loading dose of TVEC 4x106 Plaque Forming Units (PFU) on Cycle 1 Day
1 to enable the formation of protective antibodies as described in the currently approved
treatment protocol for the treatment of cutaneous melanoma. Three weeks after the initial
loading dose, patients will receive TVEC at the dose level for the cohort for which they are
enrolled every 2 weeks for up to 4 doses. The length of the first cycle is 5 weeks and
subsequent cycles are 2 weeks in duration.
The first portion of the study, the Dose Escalation cohort, will evaluate the toxicity
profile of TVEC in patients with peritoneal surface dissemination from gastrointestinal or
recurrent, platinum-resistant ovarian tumors. Using a standard '3+3' dose escalation design,
there are up to three dose levels that may be explored. Dose escalation will be dependent on
dose-limiting toxicity (DLT) within the cohorts.
Once the MTD has been determined, an additional 6 subjects will be enrolled to the dose
expansion cohort. All subjects will receive an initial loading dose of TVEC 4x106 PFU on
Cycle 1 Day 1. Three weeks after the initial loading dose, patients will receive TVEC at the
MTD every 2 weeks for up to 4 doses. The length of the first cycle is 5 weeks and the
subsequent cycles are 2 weeks in duration. There are a total of four cycles.
1. Patients must have stage IV peritoneal surface dissemination of gastrointestinal
cancer that cannot be completely resected at the time of abdominal exploration, or
recurrent, platinum-resistant ovarian cancer with peritoneal metastasese.
Radiographically measurable disease is preferable, but for patients with previously
documented gastrointestinal or ovarian cancer, for whom tumor markers (CEA or CA-125)
have been useful markers of disease progression and/or response to treatment, a rising
tumor marker (CEA or CA-125) could be substituted for radiographic imaging.
2. Subjects must have had at least one prior round of systemic therapy or have refused or
be ineligible for standard systemic therapy for their disease type.
3. Age ≥ 18 years
4. Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-2
5. Adequate marrow function as evidenced by:
1. Absolute neutrophil count (ANC) ≥ 2,000/µL
2. Platelets ≥ 100,000/µL
3. Hemoglobin (Hgb) ≥ 9 g/dL
6. Adequate renal function as evidenced by serum creatinine ≤ 1.5 x upper limit of normal
(ULN), OR 24-hour creatinine clearance ≥ 60 mL/min for subject with creatinine levels
> 1.5 x ULN.
7. Adequate hepatic function as evidenced by:
1. Serum bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ ULN for a subject with total
bilirubin level > 1.5 x ULN
2. Aspartate aminotransferase (AST) ≤ 3 x ULN
3. Alanine aminotransferase (ALT) ≤ 3 x ULN
4. Alkaline phosphatase ≤ 3 x ULN
8. INR or PT ≤ 1.5 x ULN, unless the subject is receiving anticoagulant therapy, in which
case PT and PTT/aPTT must be within therapeutic range of intended use of
anticoagulants (and may need to be held per institutional standards for placement of
the Bard peritoneal catheter).
9. Patients must be recovered from both acute and late effects of any prior surgery,
radiotherapy or other antineoplastic therapy.
10. Patients of reproductive potential (men and women) must agree to use medically
accepted barrier methods of contraception (e.g., male or female condom) at the time of
pregnancy test (women of childbearing potential only), during the course of the study
and for 90 days after the last dose of study drug, even if oral contraceptives are
also used. All subjects of reproductive potential must agree to use both a barrier
method and a second method of birth control during the course of study and for 90 days
after the last dose of study drug.
11. Patients or their legal representatives must be able to read, understand and provide
informed consent to participate in the trial.
1. Prior chemotherapy, radiotherapy, biological cancer therapy, targeted therapy, or
major surgery within 28 days prior to enrollment or has not recovered to CTCAE grade 1
or better from adverse event due to cancer therapy administered more than 28 days
prior to enrollment.
2. Patients who received radiotherapy to more than 25% of their bone marrow.
3. Currently receiving treatment with another investigational device or drug study, or <
30 days since ending treatment with another investigational device or drug study(s).
Other investigational procedures while participating in this study are excluded.
4. Known active central nervous system (CNS) metastases. Subjects with previously treated
brain metastases may participate provided they are stable (without evidence of
progression by imaging for at least four weeks prior to the first dose of trial
treatment and any neurologic symptoms have returned to baseline), have no evidence of
new or enlarging brain metastases, and are not using steroids >10 mg/day of prednisone
or equivalent. The exception does not include carcinomatous meningitis, which is
excluded regardless of clinical stability.
5. Metastatic disease in a site other than the peritoneal surfaces.
6. History or evidence of active autoimmune disease that requires systemic treatment
(i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive
drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid
replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
form of systemic treatment.
7. Evidence of clinically significant immunosuppression such as the following:
1. Primary immunodeficiency state such as Severe Combined Immunodeficiency Disease.
2. Concurrent opportunistic infection.
3. Receiving systemic immunosuppressive therapy (> 2 weeks) including oral steroid
doses >10mg/day of prednisone or equivalent within 7 days prior to enrollment.
8. History of allogenic organ or hematopoietic transplant.
9. Active herpes simplex virus (HSV) that requires intermittent or chronic systemic
anti-herpetic therapy or prior complications of herpetic infection, e.g. herpetic
keratitis or encephalitis.
10. Requiring intermittent or chronic systemic (intravenous or oral) treatment with an
antiherpetic drug (e.g., acyclovir), other than intermittent topical use.
11. Prior treatment with talimogene laherparepvec or any other oncolytic virus.
12. Subject has known sensitivity to talimogene laherparepvec or any of its components to
be administered during dosing.
13. Prior therapy with tumor vaccine.
14. Receipt of a live vaccine within 28 days prior to enrollment.
15. Known to have acute or chronic active hepatitis B or C infection (active, previously
treated, or both).
16. Known history of HIV infection.
17. Active infection or fever ≥ 101.3°F within 3 days of the first scheduled day of
18. Peripheral neuropathy ≥ Grade 2.
19. Bleeding disorders that would preclude intraperitoneal port placement.
20. Refractory ascites that requires palliative paracentesis more frequently than once a
month. Any other medical condition, including mental illness or substance abuse,
deemed by the Investigator to be likely to interfere with a patient's ability to sign
informed consent, cooperate and participate in the study or interferes with the
interpretation of the results.
21. History of other malignancy within the past 5 years.
22. Female subjects who are pregnant or breast-feeding, or planning to become pregnant
during study treatment or through 90 days after the last dose of talimogene
23. Subjects of childbearing potential who are unwilling to use acceptable method(s) of
effective contraception during study treatment and through 90 days after the last dose
of talimogene laherparepvec.
24. Sexually active subjects and their partners unwilling to use male or female latex
condom to avoid potential viral transmission during sexual contact while on treatment
and within 90 days after treatment with talimogene laherpareapvec.